Articles tagged with Covid 19 Vaccines
Researchers developed a new method to quantify the structure and quality of messenger RNA (mRNA) medicines using liquid chromatography, mass spectrometry, and software analysis. The platform can analyze all three key components of mRNA medicines simultaneously, providing unparalleled efficiency in checking for quality.
Researchers from the University of Colorado found that Paxlovid significantly reduced rates of hospitalization and death among non-hospitalized patients infected with recent Omicron subvariants. The study used real-world data from 28,000 patients and suggested a benefit for Paxlovid in preventing severe disease.
A recent study monitored the Italian province of Pescara for 18 months and found no increased risk of serious diseases among vaccinated individuals. The study revealed that vaccinated persons were more protected against COVID-19 and had lower rates of deaths and disease occurrences compared to non-vaccinated individuals.
A recent study published by The BMJ found that COVID-19 vaccination during pregnancy may have benefits for both mother and baby. Two doses of mRNA Covid-19 vaccine were highly effective against delta infection, while two doses against omicron infection showed moderate effectiveness. A third dose during pregnancy also bolstered protecti...
A study by Brown University researchers found that night shift nursing home staff had significantly lower rates of COVID-19 testing and primary vaccination compared to day shift staff. The study highlights the importance of considering work shifts in designing workplace health interventions.
A recent study found that individuals with conservative political leanings tend to favor hydroxychloroquine and view vaccination unfavorably. Physicians also exhibit similar biases, with conservative physicians being more likely to prescribe hydroxychloroquine. The study suggests that education alone may not be enough to combat polariz...
A Rutgers study found that people who know someone who became ill with COVID-19 or died from the disease are twice as likely to receive a COVID-19 vaccine. The study also found that essential workers and those with better health status were more likely to get vaccinated.
A large Dutch study found that the BCG vaccine does not protect elderly people with co-morbidities against COVID-19 symptoms. The study analyzed 6,112 participants and showed no difference in disease manifestations or hospitalizations between those who received the vaccine and those who received a placebo.
Researchers develop eRapid sensor technology to detect SARS-CoV-2 antibodies, enabling fast and multiplexed testing at the point-of-care. The device distinguishes between antibody types targeting different viral proteins with high sensitivity and specificity.
Suboptimal COVID-19 vaccination coverage was found in a study of 5.6 million US veterans, with younger and rural veterans showing lower rates of primary vaccination and booster shots needed for all veterans
Researchers developed a new way to increase vaccine potency by changing the structural location of antigens and adjuvants. This approach, called 'rational vaccinology,' allows for precise dosing and tailored presentation of vaccine components, leading to improved immune response and cancer cell targeting.
A Hong Kong study published in Canadian Medical Association Journal found a 90% reduction in COVID-19 deaths among adults with multimorbidity who received a booster dose of vaccine. The study, which included over 120,000 participants, suggests that booster vaccination can significantly lower mortality rates in vulnerable populations.
A study by researchers in Brazil found that loss of muscle mass during COVID-19 hospitalization is associated with the development of persistent symptoms such as weakness, shortness of breath, and fatigue. The study also showed that patients who lost more muscle mass had higher healthcare costs six months after discharge.
A study by OHSU researchers found that immunity from COVID-19 gathers strength over time, indicating that vaccination should not be delayed. The study suggests that vaccine boosters can be spaced no more frequently than a year apart among healthy individuals.
A new COVID-19 vaccine has been tested in humans, showing a good immune response and few side effects. The effectiveness of the vaccine is currently being investigated, but initial results suggest it could provide long-lasting immunity.
A peer-reviewed study published in The New England Journal of Medicine found that updated bivalent mRNA vaccines are more effective than original monovalent boosters at preventing COVID-19 hospitalization and death. Booster effectiveness peaked at four weeks after receipt and waned afterward, with average effectiveness against severe i...
The COVID-19 Prevention Network's coordinated approach to Phase 3 clinical trials has yielded a comprehensive database of trial participants' data. This dataset will help researchers address pressing questions about SARS-CoV-2 and inform future vaccine development.
A systematic review and meta-analysis of 17 studies found mRNA COVID-19 vaccination to be associated with lower risks of SARS-CoV-2 infections, severe illnesses, and hospitalizations. While vaccination was linked to higher adverse event rates, the frequency of severe adverse events remained low.
Researchers from UCalgary and the World Health Organization found that people with hybrid immunity have the highest level of protection against severe illness and reinfection, offering a key finding for public policy makers. The study suggests vaccination should be prioritized even among those who have had COVID-19.
A recent study of over 42,000 patients found low adherence to COVID-19 booster dose recommendations among immunocompromised individuals. This vulnerable population faces increased risk of severe COVID-19, underscoring the importance of tailored efforts to ensure they remain up-to-date with booster doses.
A new study provides evidence on when OAS occurs and how it impacts seasonal vaccines and booster shots. The findings suggest that boosting against a new strain can be effective if the new strain is sufficiently different from the previous one.
A new paper proposes sharing intellectual property rights to vaccines with the global community to increase access and potentially save millions of lives. By doing so, companies can raise prices for medicines under patents and sell them only to those willing to pay the most to maximize profits.
A massive global survey found that accurate information about others' vaccination status can substantially increase intentions to accept a COVID-19 vaccine. The study shows people greatly underestimate vaccine uptake both worldwide and in their own communities.
A new study reveals that high-affinity B cells trigger a change in the criteria for admission to germinal centers, allowing low-affinity B cells to join, increasing the diversity of the immune response. This process is crucial for fighting off viruses like SARS-CoV-2 but may hinder efforts against HIV.
Scientists have identified a new class of 'bivalent' antibodies that can bind to two viral targets at once, neutralizing multiple Omicron variants. These potent antibodies retain efficacy against early SARS-CoV-2 variants and several later Omicron sub-lineages.
A new study found that COVID-19 infection in pregnant women significantly increases the risk of death, ICU admission, and preterm birth. The research highlights the need for COVID-19 vaccination among women of childbearing age to prevent these serious health risks.
A pooled data analysis of international evidence finds that COVID-19 infection during pregnancy nearly doubles the risk of maternal death and severe illness. Babies born to infected mothers are also at increased risk of premature birth and low birth weight.
A new study published in the Journal of Perinatology found that breast milk from vaccinated parents contains antibodies that provide protection to infants. The study analyzed stool samples from 25 infants and found SARS-CoV-2 antibodies, which offer protection against the virus.
A study by Yale School of Public Health and University of North Carolina at Charlotte found that annual or biannual COVID-19 boosters significantly reduce the risk of future infection. Boosting every six months provides strong suppression of infection, with only one in 10 people projected to contract COVID-19 over a six-year period.
A large study found that most symptoms of long COVID resolve within a year after a mild COVID-19 infection. Vaccinated people were at lower risk of breathing difficulties, the most common effect to develop after mild infection, compared with unvaccinated people.
A novel imaging agent, 68Ga-FAPI, has been shown to reduce the number of false-positive PET/CT findings among cancer patients recently vaccinated for COVID-19. This can help prevent costly follow-up and false management decisions for cancer patients.
A new study by University of Kent researchers identifies 'distrustful complacency' as a key factor behind vaccine resistance, highlighting the importance of both public concern and political trust in driving vaccination uptake.
A new analysis by Cedars-Sinai investigators shows that similar levels of COVID-19 antibodies are reached over an extended period of time in different population groups. Individuals with autoimmune diseases and solid organ transplant patients experience lower long-term antibody levels.
A mathematical model predicts the long-term effectiveness of COVID-19 vaccine booster doses in various patient populations, including those with healthy immune systems and cancer patients. The model suggests that robust antibody-based responses can be achieved through booster doses, but may wane quickly in immunosuppressed individuals.
A new survey of 23 countries found that global willingness to accept a COVID-19 vaccine increased from 75.2% in 2021 to 79.1% in 2022. However, eight countries experienced an increase in hesitancy, and nearly one in eight vaccinated respondents were hesitant about receiving booster doses. The survey also revealed variations in vaccine ...
Researchers developed a CSIC vaccine that fully protects against SARS-CoV-2 infection in the brain and prevents associated brain damage. The MVA-CoV2-S vaccine candidate demonstrates sterilizing immunity and was effective even after reinfection with the virus.
A new survey of 23 countries found a 5.2% increase in COVID-19 vaccine acceptance from 2021 to 2022, but also detected increased hesitancy in several countries, particularly among younger men and women.
A study found that 6.5% of the general population in Spain hesitated to receive the COVID-19 vaccine, with younger and less educated individuals being more reluctant. In contrast, healthcare professionals showed higher vaccination rates and had fewer concerns about the vaccine's effectiveness.
A new study in Portugal's population shows that hybrid immunity from vaccination and previous SARS-CoV-2 infections confers up to 8 months of protection against omicron BA.5. The study found that protection remains high after 8 months, with a stable level of around 65%.
A study by Mass General Brigham found elevated levels of spike protein, increased cytokines, and troponin in the blood of 16 adolescents and young adults who developed myocarditis after COVID mRNA vaccination. The researchers also discovered no differences in antibody production or auto-antibodies between cases and controls.
A multicenter study found that COVID-19 vaccination following multisystem inflammatory syndrome (MIS-C) is safe, with mild reactions and no serious complications. The study included 385 patients aged 5 years or older, all of whom received at least one vaccine dose without any reports of myocarditis or MIS-C reoccurrence.
A study of 385 patients with a history of multisystem inflammatory syndrome in children found no serious COVID-19 vaccine reactions. The vaccine's safety profile appears comparable to that of the general population, at least 90 days after MIS-C diagnosis.
A study in California prisons found that recent vaccination and boosters significantly reduced infectiousness of COVID-19, with a 11% decrease per additional dose. Prior infection also provided protection, with a 23% risk of transmission compared to 33% for those who had never been infected.
A US study of 15,000 nursing homes found that pre-Omicron vaccination boosts reduced COVID-19 cases and deaths among residents and staff. Newer variants rendered original vaccine less effective.
Patients with cancer are at a higher risk of SARS-CoV-2 infection and worse outcomes than those without cancer. Triple vaccination is associated with a lower risk of poor outcomes in these patients.
The study found that COVID-19 vaccination in patients with blood cancer activates a strong T cell response, providing protection against serious illness. Patients who form antibodies tend to produce high-quality antibodies capable of neutralizing different SARS-CoV-2 variants.
A new study from the University of Virginia Health System found that mRNA booster shots increase the durability of antibodies to COVID-19. The boosters led to longer-lasting antibodies, even in those who had previously recovered from a COVID-19 infection.
A study published in The BMJ found that people who believe in conspiracies and reject the covid-19 vaccine are more likely to endorse mythical causes of cancer than non-conspiracists. However, awareness of actual causes of cancer is generally higher among these groups.
A study in Serrana, Brazil showed that mass vaccination reduced severe cases and death rates even while gamma and delta variants were circulating. Vaccination coverage reached 80% of the target population.
A new study reveals that Chinese Communist Party zero-covid volunteers have suffered from stress and anxiety due to the pressure of enforcing policies. The researchers found an increasingly pressurized grassroots infrastructure, with volunteers facing high workloads and hierarchical chains of command.
A multi-state study found that bivalent booster vaccines significantly reduce COVID-19-related emergency department or urgent care visits and hospitalization rates. The study showed a 57% reduction in COVID-19 related emergency department or urgent care visits compared to unvaccinated adults.
New research reveals that COVID-19 nasal antibodies provide first-line defence but decline nine months after infection, while blood antibodies last at least a year. Vaccination boosts blood antibodies to prevent severe disease, but has limited effect on nasal IgA levels.
A new respiratory vaccine has been shown to provide complete protection against lethal SARS-CoV-2 challenge in mice. The vaccine uses a DNA encoding a viral protein and is delivered through the mucous membranes, targeting immune cells in the nose and lungs.
A large real-world study has confirmed that COVID-19 vaccination is more effective than natural immunity in preventing death, hospitalizations, and emergency department visits for any cause. Vaccinated individuals had a 37% lower risk of all-cause death and hospital admission rates compared to those with natural immunity.
A large Finnish study of 5.5 million residents found no evidence of an increased risk of sudden sensorineural hearing loss following COVID-19 vaccination. The study controlled for previous disease and other potential confounding factors, providing reassurance about the safety of COVID-19 vaccines.
Researchers developed a method to produce SARS-CoV-2 RBD antigen using bio-engineered plants, offering a scalable solution for diagnostic assays and subunit vaccines. This breakthrough could facilitate large-scale production of antigens, supporting global vaccination efforts.
The Pfizer-BioNTech COVID-19 vaccine provided modest short-term protection against Omicron infection among children ages 5 to 11, with higher effectiveness for those with prior infection; a booster dose restored and maintained protection for at least three months.
A recent study published in the American Journal of Obstetrics & Gynecology MFM found that pregnant individuals have a similar long-term immune response to SARS-CoV-2 mRNA vaccination as non-pregnant individuals. The study also showed that vaccination during pregnancy provides protection to unborn babies, which is essential for their C...
Researchers found that adult hospitalisations from Omicron-related SARS-CoV-2 infections were less severe than those from Delta infections. The Pfizer-BioNTech vaccine was effective in preventing hospitalisations and severe outcomes, even with increasing Omicron variant transmissibility.
A new study in The American Journal of Medicine found that adults who neglect COVID-19 vaccination may also neglect basic road safety guidelines. Unvaccinated individuals were more likely to be involved in traffic crashes, with a 72% increased relative risk compared to those vaccinated.